Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Fund Type: SICAV
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: International

Credit Suisse Lux Biotechnology Equity Fund

+ Add to Watchlist

CR4A:GR

397.7200 EUR 5.6080 1.43%

As of 09:42:18 ET on 01/30/2015.

Snapshot for Credit Suisse Lux Biotechnology Equity Fund (CR4A)

Open: 389.0600 High - Low: 397.7200 - 388.6600 Primary Exchange: Berlin
Volume: 0 52-Week Range: 201.6000 - 403.0600 Beta vs NBI: 0.9622

ETF Chart for CR4A

No chart data available.
  • CR4A:GR 389.6360
  • 1D
  • 1M
  • 1Y
392.1120
Interactive CR4A Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for CR4A

Credit Suisse Lux Biotechnology Equity Fund is a SICAV incorporated in Luxembourg. The Fund is actively managed aiming to outperform the return of the NASDAQ Biotechnology TR benchmark. The Fund mainly invests in equity and equity-type securities of issuers engaged in the biotechnology industry.

Inception Date: 2001-11-06 Telephone: -
Managers: IRENE BEATRICE PUETTNER
Web Site: www.credit-suisse.com

Fundamentals for CR4A

NAV -
Assets (M) (on 2015-01-29) 236.8260
Shares out (M) 0.47
Market Cap (M) 186.55
% Premium -
Average 52-Week % Premium -
Fund Leveraged N

Dividends for CR4A

No dividends reported

Performance for CR4A

1-Month +15.28% 1-Year +56.13%
3-Month +25.00% 3-Year +48.18%
Year To Date +15.28% 5-Year +33.71%
Expense Ratio -

Top Fund Holdings for CR4A

Filing Date: 10/31/2014
Name Position Value % of Total
Gilead Sciences Inc 162,484 18,198,208 8.274%
Amgen Inc 105,973 17,186,701 7.814%
Celgene Corp 160,276 17,163,957 7.803%
Biogen Idec Inc 42,745 13,724,565 6.240%
Regeneron Pharmaceuticals Inc 27,000 10,630,440 4.833%
Incyte Corp 153,000 10,260,180 4.665%
Vertex Pharmaceuticals Inc 90,000 10,137,600 4.609%
Alexion Pharmaceuticals Inc 52,752 10,094,623 4.589%
BioMarin Pharmaceutical Inc 115,444 9,524,130 4.330%
Medivation Inc 80,000 8,456,000 3.844%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil